Sanofi's Dengue Vaccine Is World's First Approved
This article was originally published in Scrip
The first vaccine against the world's fastest growing mosquito-borne disease, dengue virus, has been granted marketing authorisation in Mexico. Sanofi Pasteur's Dengvaxia has been approved for prevention against four dengue virus serotypes in adults, adolescents and pre-adolescents, aged 9-45 years, by the COFEPRIS (The Federal Commission for the Protection against Sanitary Risks).
You may also be interested in...
The French drug manufacturer admits the world’s first dengue vaccine may be harmful when administered to individuals not previously infected with the disease.
Long-term Phase II data have backed Takeda's drive to study its dengue vaccine in Phase III, but to grow the market the company may have to reverse the reluctance of countries to fund public vaccination campaigns.
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.